Mark Bloch

5.6k citations

58 papers · 2.5k · 2 hit papers · h-index 21

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 30
- HIV/AIDS drug development and treatment 20
- HIV/AIDS Research and Interventions 15
Virology 16
- HIV Research and Treatment 16

Co-authors: Roy G. D’Andrade (1 shared paper)Don Smith (7 shared papers)David A. Cooper (8 shared papers)François Raffi (2 shared papers)Sherene Min (2 shared papers)Anita Rachlis (2 shared papers)Robert Finlayson (10 shared papers)John Zaunders (4 shared papers)
Journals: AIDS (7 papers)HIV Medicine (4 papers)Journal of Hepatology (4 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)HIV Clinical Trials (3 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Mark Bloch

56 papers receiving 2.2k citations

Mark Bloch's Hit Papers

align trajectories log scale

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study 2013 · 421 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 The Lancet
1997 Journal of the Royal Anthropological Institute

Peers

Countries citing papers authored by Mark Bloch

Since Specialization

Citations

This map shows the geographic impact of Mark Bloch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bloch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bloch more than expected).

Fields of papers citing papers by Mark Bloch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bloch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bloch. The network helps show where Mark Bloch may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Bloch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Bloch Line = papers co-authored together Mark Bloch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The Development of Cognitive Anthropology. Journal of the Royal Anthropological Institute ·Mark Bloch, Roy G. D’Andrade Hit paper breakdown →	1997	867
2	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study The Lancet ·François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink, W. D. Hardy, Carlo Torti, Chloe Orkin, Mark Bloch, Daniel Podzamczer, Vadim Pokrovsky, Federico Pulido, Steve Almond, David M. Margolis, Clare Brennan, Sherene Min Hit paper breakdown →	2013	421
3	The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy AIDS ·Gilbert R. Kaufmann, Mark Bloch, Robert Finlayson, John Zaunders, Don Smith, David A. Cooper	2002	139
4	Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults AIDS ·Calvin Cohen, David A. Wohl, José Ramón Arribas, Keith Henry, Jan van Lunzen, Mark Bloch, William Towner, Edmund Wilkins, Ramin Ebrahimi, Danielle Porter, Kirsten White, Ivan Walker, Susan K. Chuck, Shampa De-Oertel, Todd Fralich	2014	95
5	Impact of Therapeutic Immunization on HIV‐1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection The Journal of Infectious Diseases ·Sabine Kinloch‐de Loes, Bruno Hoen, Don Smith, Brigitte Autran, Fiona Lampe, Andrew Phillips, Li‐Ean Goh, Jan Andersson, Christos Tsoukas, Anders Sönnerborg, Giuseppe Tambussi, Pierre‐Marie Girard, Mark Bloch, Manuel Battegay, Nick Carter, Raphaëlle El Habib, Georgia Theofan, David A. Cooper, Luc Perrin, (unknown)	2005	81
6	A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review Clinical Infectious Diseases ·Mark Bloch, Jody Kamminga, Avindra F. Jayewardene, Michael Bailey, Angela E. Carberry, Trina Vincent, Dick Quan, Paul Maruff, Bruce J. Brew, Lucette A. Cysique	2016	63
7	Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy AIDS ·Krista J. Siefried, Limin Mao, Lucette A. Cysique, John Rule, Michelle Giles, Don Smith, James McMahon, Tim Read, Catriona Ooi, Ban Kiem Tee, Mark Bloch, John de Wit, Andrew Carr	2017	63
8	Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir AIDS ·Kersten K. Koelsch, Christoph Boesecke, Kristin McBride, Linda Gelgor, Paul Fahey, Ven Natarajan, David Baker, Mark Bloch, John M. Murray, John Zaunders, Sean Emery, David A. Cooper, Anthony D. Kelleher	2011	60
9	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies HIV Clinical Trials ·Mark Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal‐Maurer, Mark Bloch, Will Garner, Bill Guyer, Scott Williams, S.K. Chuck, Simon Vanveggel, H. Deckx, Marita Stevens	2013	47
10	Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic British Journal of Clinical Pharmacology ·John E. Ray, Debbie Marriott, Mark Bloch, Andrew J. McLachlan	2005	46
11	Managing HIV‐associated inflammation and ageing in the era of modern ART HIV Medicine ·Mark Bloch, Mina John, Don Smith, Thomas A. Rasmussen, Edwina Wright	2020	45
12	Frailty in people living with HIV AIDS Research and Therapy ·Mark Bloch	2018	40
13	Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years—The Australian Positive & Peers Longevity Evaluation Study (APPLES) PLoS ONE ·Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J. Templeton, David Baker, Michelle Giles, Matthew Law, David A. Cooper	2017	40
14	Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients HIV Clinical Trials ·Lloyd Curtis, Garrett Nichols, Chris Stainsby, Jessica Lim, Alicia Aylott, Brian Wynne, Andrew Clark, Mark Bloch, Gudrun Maechler, Louise Martin-Carpenter, François Raffi, Sherene Min	2014	34
15	Activation of NK Cells by ADCC Responses During Early HIV Infection Viral Immunology ·Amy W. Chung, Marjon Navis, Gamze Isitman, Robert Finlayson, Mark Bloch, Linda Gelgor, Antony Kelleher, Stephen J. Kent, Ivan Stratov	2011	32
16	Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults AIDS ·Jan van Lunzen, Andrea Antinori, Calvin Cohen, José Ramón Arribas, David A. Wohl, Armin Rieger, Anita Rachlis, Mark Bloch, Sorana Segal‐Maurer, Will Garner, Danielle Porter, Matthew Bosse, David Piontkowsky, Susan K. Chuck, Shampa De-Oertel	2015	32
17	High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE AIDS and Behavior ·(unknown), Iryna Zablotska, Stefanie Vaccher, Mark Bloch, Andrew Carr, Rosalind Foster, Andrew E. Grulich, Rebecca Guy, Anna McNulty, Catriona Ooi, Catherine Pell, I. Mary Poynten, Garrett Prestage, Nathan Ryder, David J. Templeton	2018	28
18	Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy AIDS Research and Human Retroviruses ·William J. Hey-Nguyen, Yin Xu, Chester F. Pearson, Michelle Bailey, Kazuo Suzuki, Robyn Tantau, Solange Obeid, Brad Milner, Andrew Field, Andrew Carr, Mark Bloch, David A. Cooper, Anthony D. Kelleher, John Zaunders, Kersten K. Koelsch	2017	26
19	Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy Human Vaccines ·Sean Emery, Anthony D. Kelleher, Cassy Workman, Rebekah Puls, Mark Bloch, David Baker, J. Anderson, Jennifer Hoy, Stephen Ip, K. Nalliah, Lucas D. Ward, Matthew Law, David A. Cooper	2007	24
20	Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-? in HIV-1 Infected Subjects Human Vaccines ·Sean Emery, Cassy Workman, Rebekah Puls, Mark Bloch, David Baker, Neil Bodsworth, J. Anderson, Suzanne M. Crowe, Martyn A. French, Jennifer Hoy, A Aichelburg, Lucas D. Ward, DB BOYLE, Matthew Law, Anthony D. Kelleher, David A. Cooper	2005	24

About Mark Bloch

Mark Bloch is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Hepatology, having authored 58 papers that have together received 2.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (20 papers), HIV Research and Treatment (16 papers), HIV/AIDS Research and Interventions (15 papers), HIV-related health complications and treatments (13 papers), Hepatitis C virus research (9 papers), Liver Disease Diagnosis and Treatment (3 papers), Herpesvirus Infections and Treatments (3 papers) and HIV, Drug Use, Sexual Risk (3 papers). The work is most often cited by research in Virology (708 citations), Infectious Diseases (909 citations), Emergency Medicine (329 citations), Experimental and Cognitive Psychology (211 citations) and Social Psychology (225 citations). Mark Bloch has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Roy G. D’Andrade, Don Smith, David A. Cooper, François Raffi, Sherene Min, Anita Rachlis, Robert Finlayson, John Zaunders, Chloe Orkin and Daniel Podzamczer. Their work appears in journals such as AIDS, HIV Medicine, Journal of Hepatology, JAIDS Journal of Acquired Immune Deficiency Syndromes and HIV Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark Bloch

Impact in

Papers in i

In The Last Decade

Mark Bloch

Mark Bloch's Hit Papers

Peers

Countries citing papers authored by Mark Bloch

Fields of papers citing papers by Mark Bloch

All Works

About Mark Bloch

Explore authors with similar magnitude of impact

Papers in